Central dopaminergic system and its implications in stress-mediated neurological disorders and gastric ulcers: Short review

Advances in Pharmacological Sciences

Volumn 2012, Issue , 2012, Pages

  Rasheed, Naila ^a   Alghasham, Abdullah ^a  

^a QASSIM UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTERONE; DOPAMINE; PROSTAGLANDIN E2;

ADDICTION; COPING BEHAVIOR; DOPAMINERGIC SYSTEM; HUMAN; NEUROLOGIC DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCHIZOPHRENIA; STRESS ULCER;

EID: 84867389281     PISSN: 16876334     EISSN: 16876342     Source Type: Journal    
DOI: 10.1155/2012/182671     Document Type: Review

References (114)

1. Sarkar C., Basu B., Chakroborty D., Dasgupta P. S., Basu S., The immunoregulatory role of dopamine: an update. Brain, Behavior, and Immunity 2010 24 4 525 528 2-s2.0-77951880839 10.1016/j.bbi.2009.10.015
2. Nieoullon A., Coquerel A., Dopamine: a key regulator to adapt action, emotion, motivation and cognition. Current Opinion in Neurology 2003 16 supplement 2 S3 S9 2-s2.0-1342301451 (Pubitemid 38251045)
3. Benturquia N., Courtin C., Noble F., Marie-Claire C., Involvement of D1 dopamine receptor in MDMA-induced locomotor activity and striatal gene expression in mice. Brain Research 2008 1211 1 5 2-s2.0-43049179810 10.1016/j.brainres.2008.03.016
4. Pani L., Porcella A., Gessa G. L., The role of stress in the pathophysiology of the dopaminergic system. Molecular Psychiatry 2000 5 1 14 21 2-s2.0-0033966893 (Pubitemid 30088448)
5. Varga J., Domokos A., Barna I., Jankord R., Bagdy G., Zelena D., Lack of vasopressin does not prevent the behavioural and endocrine changes induced by chronic unpredictable stress. Brain Research Bulletin 2011 84 1 45 52 2-s2.0-78650304525 10.1016/j.brainresbull.2010.09.014
6. Brunelin J., d'Amato T., van Os J., Cochet A., Suaud-Chagny M. F., Saoud M., Effects of acute metabolic stress on the dopaminergic and pituitary-adrenal axis activity in patients with schizophrenia, their unaffected siblings and controls. Schizophrenia Research 2008 100 13 206 211 2-s2.0-40149083573 10.1016/j.schres.2007.11.009
7. Daftary S. S., Panksepp J., Dong Y., Saal D. B., Stress-induced, glucocorticoid-dependent strengthening of glutamatergic synaptic transmission in midbrain dopamine neurons. Neuroscience Letters 2009 452 3 273 276 2-s2.0-60849131709 10.1016/j.neulet.2009.01.070
8. Craenenbroeck K. V., Bosscher K. D., Berghe W. V., Vanhoenacker P., Haegeman G., Role of glucocorticoids in dopamine-related neuropsychiatric disorders. Molecular and Cellular Endocrinology 2006 245 1-2 10 22 2-s2.0-30044451550 10.1016/j.mce.2005.10.007 (Pubitemid 43049741)
9. Cabib S., Puglisi-Allegra S., The mesoaccumbens dopamine in coping with stress. Neuroscience and Biobehavioral Reviews 2012 36 1 79 89 2-s2.0-79955966017 10.1016/j.neubiorev.2011.04.012
10. Rasheed N., Ahmad A., Pandey C. P., Chaturvedi R. K., Lohani M., Palit G., Differential response of central dopaminergic system in acute and chronic unpredictable stress models in rats. Neurochemical Research 2010 35 1 22 32 2-s2.0-76849113946 10.1007/s11064-009-0026-5
11. Pohorecky L. A., Sweeny A., Buckendahl P., Differential sensitivity to amphetamine's effect on open field behavior of psychosocially stressed male rats. Psychopharmacology 2011 218 1 281 292 2-s2.0-79959201027 10.1007/s00213-011-2339-8
12. Salamone J. D., Correa M., Mingote S. M., Weber S. M., Beyond the reward hypothesis: alternative functions of nucleus accumbens dopamine. Current Opinion in Pharmacology 2005 5 1 34 41 2-s2.0-12344308143 10.1016/j.coph.2004.09.004 (Pubitemid 40124532)
13. Floresco S. B., Dopaminergic regulation of limbic-striatal interplay: 2006 CCNP Young Investigator Award. Journal of Psychiatry and Neuroscience 2007 32 6 400 411 2-s2.0-37049010134 (Pubitemid 350248226)
14. Lodge D. J., Grace A. A., Developmental pathology, dopamine, stress and schizophrenia. International Journal of Developmental Neuroscience 2011 29 3 207 213 2-s2.0-79953667820 10.1016/j.ijdevneu.2010.08.002
15. Ozdemir V., Jamal M. M., Osapay K., Jadus M. R., Sandor Z., Hashemzadeh M., Szabo S., Cosegregation of gastrointestinal ulcers and schizophrenia in a large national inpatient discharge database: revisiting the brain-gut axis hypothesis in ulcer pathogenesis. Journal of Investigative Medicine 2007 55 6 315 320 2-s2.0-36749020653 10.2310/6650.2007.00014 (Pubitemid 350205426)
16. Brzozowski T., Konturek P. C., Konturek S. J., Kwiecie S., Drozdowicz D., Bielanski W., Pajdo R., Ptak A., Nikiforuk A., Pawlik W. W., Hahn E. G., Exogenous and endogenous ghrelin in gastroprotection against stress-induced gastric damage. Regulatory Peptides 2004 120 13 39 51 2-s2.0-1842423853 10.1016/j.regpep.2004.02.010 (Pubitemid 38726190)
17. Landeira-Fernandez J., Grijalva C. V., Participation of the substantia nigra dopaminergic neurons in the occurrence of gastric mucosal erosions. Physiology and Behavior 2004 81 1 91 99 2-s2.0-1842418476 10.1016/j.physbeh. 2004.01.004 (Pubitemid 38430045)
18. Nishikawa K., Amagase K., Takeuchi K., Effect of dopamine on the healing of acetic acid-induced gastric ulcers in rats. Inflammopharmacology 2007 15 5 209 213 2-s2.0-35349020046 10.1007/s10787-007-1594-0 (Pubitemid 47609388)
19. Saad S. F., Agha A. M., Amrin A. E. N. S., Effect of bromazepam on stress-induced gastric ulcer in rats and its relation to brain neurotransmitters. Pharmacological Research 2001 44 6 495 501 2-s2.0-0035659296 10.1006/phrs.2001.0894 (Pubitemid 34014330)
20. Degen S. B., Geven E. J. W., Sluyter F., Hof M. W. P., van der Elst M. C. J., Cools A. R., Apomorphine-susceptible and apomorphine-unsusceptible Wistar rats differ in their recovery from stress-induced ulcers. Life Sciences 2003 72 10 1117 1124 2-s2.0-0037462286 10.1016/S0024-3205(02)02362-7 (Pubitemid 36054167)
21. Selye H., Stress and the general adaptation syndrome. British Medical Journal 1950 1 4667 1383 1392 2-s2.0-0000221213
22. Radley J. J., Gosselink K. L., Sawchenko P. E., A discrete GABAergic relay mediates medial prefrontal cortical inhibition of the neuroendocrine stress response. Journal of Neuroscience 2009 29 22 7330 7340 2-s2.0-66749120702 10.1523/JNEUROSCI.5924-08.2009
23. Asanuma M., Miyazaki I., Ogawa N., Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotoxicity Research 2003 5 3 165 176 2-s2.0-0038159674 10.1007/BF03033137
24. Steketee J. D., Kalivas P. W., Drug wanting: behavioral sensitization and relapse to drug-seeking behavior. Pharmacological Reviews 2011 63 2 348 365 2-s2.0-79955771120 10.1124/pr.109.001933
25. Cabib S., Puglisi-Allegra S., Stress, depression and the mesolimbic dopamine system. Psychopharmacology 1996 128 4 331 342 2-s2.0-0029902505 10.1007/s002130050142 (Pubitemid 26417674)
26. Jaber M., Robinson S. W., Missale C., Caron M. G., Dopamine receptors and brain function. Neuropharmacology 1996 35 11 1503 1519 2-s2.0-0030458318 10.1016/S0028-3908(96)00100-1 (Pubitemid 27026480)
27. Missale C., Nash S. R., Robinson S. W., Jaber M., Caron M. G., Dopamine receptors: from structure to function. Physiological Reviews 1998 78 1 189 225 2-s2.0-6844250767 (Pubitemid 28070979)
28. Imperato A., Angelucci L., Casolini P., Zocchi A., Puglisi-Allegra S., Repeated stressful experiences differently affect limbic dopamine release during and following stress. Brain Research 1992 577 2 194 199 2-s2.0-0026598438 10.1016/0006-8993(92)90274-D
29. Belda X., Armario A., Dopamine D1 and D2 dopamine receptors regulate immobilization stress-induced activation of the hypothalamus-pituitary-adrenal axis. Psychopharmacology 2009 206 3 355 365 2-s2.0-70349566397 10.1007/s00213-009-1613-5
30. Jahng J. W., Ryu V., Yoo S. B., Noh S. J., Kim J. Y., Lee J. H., Mesolimbic dopaminergic activity responding to acute stress is blunted in adolescent rats that experienced neonatal maternal separation. Neuroscience 2010 171 1 144 152 2-s2.0-77957859503 10.1016/j.neuroscience.2010.08.063
31. Broom S. L., Yamamoto B. K., Effects of subchronic methamphetamine exposure on basal dopamine and stress-induced dopamine release in the nucleus accumbens shell of rats. Psychopharmacology 2005 181 3 467 476 2-s2.0-26944472761 10.1007/s00213-005-0007-6 (Pubitemid 41480895)
32. Radley J. J., Sawchenko P. E., A common substrate for prefrontal and hippocampal inhibition of the neuroendocrine stress response. Journal of Neuroscience 2011 31 26 9683 9695 2-s2.0-79959983796 10.1523/JNEUROSCI.6040-10. 2011
33. Uehara T., Sumiyoshi T., Matsuoka T., Itoh H., Kurachi M., Effect of prefrontal cortex inactivation on behavioral and neurochemical abnormalities in rats with excitotoxic lesions of the entorhinal cortex. Synapse 2007 61 6 391 400 2-s2.0-34147145870 10.1002/syn.20383 (Pubitemid 46559536)
34. Stuber G. D., Sparta D. R., Stamatakis A. M., van Leeuwen W. A., Hardjoprajitno J. E., Cho S., Tye K. M., Kempadoo K. A., Zhang F., Deisseroth K., Bonci A., Excitatory transmission from the amygdala to nucleus accumbens facilitates reward seeking. Nature 2011 475 7356 377 380 2-s2.0-79960635098 10.1038/nature10194
35. Harden D. G., King D., Finlay J. M., Grace A. A., Depletion of dopamine in the prefrontal cortex decreases the basal electrophysiological activity of mesolimbic dopamine neurons. Brain Research 1998 794 1 96 102 2-s2.0-0032565639 10.1016/S0006-8993(98)00219-4 (Pubitemid 28298870)
36. Moore H., Rose H. J., Grace A. A., Chronic cold stress reduces the spontaneous activity of ventral tegmental dopamine neurons. Neuropsychopharmacology 2001 24 4 410 419 2-s2.0-0035132086 10.1016/S0893- 133X(00)00188-3 (Pubitemid 32157557)
37. Groeneweg F. L., Karst H., de Kloet E. R., Joëls M., Rapid non-genomic effects of corticosteroids and their role in the central stress response. Journal of Endocrinology 2011 209 2 153 167 2-s2.0-79955527505 10.1530/JOE-10-0472
38. Tafet G. E., Bernardini R., Psychoneuroendocrinological links between chronic stress and depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2003 27 6 893 903 2-s2.0-0141628436 10.1016/S0278-5846(03) 00162-3 (Pubitemid 37141377)
39. Rasheed N., Ahmad A., Singh N., Singh P., Mishra V., Banu N., Lohani M., Sharma S., Palit G., Differential response of A 68930 and sulpiride in stress-induced gastric ulcers in rats. European Journal of Pharmacology 2010 643 1 121 128 2-s2.0-77955052131 10.1016/j.ejphar.2010.06.032
40. Rasheed N., Ahmad A., Al Sheeha M., Alghasham A., Palit G., Neuroprotective and anti-stress effect of A 68930 in acute and chronic unpredictable stress model in rats. Neuroscience Letters 2011 504 2 151 155 10.1016/j.neulet.2011.09.021
41. Mizoguchi K., Ishige A., Takeda S., Aburada M., Tabira T., Endogenous glucocorticoids are essential for maintaining prefrontal cortical cognitive function. Journal of Neuroscience 2004 24 24 5492 5499 2-s2.0-3042597733 10.1523/JNEUROSCI.0086-04.2004 (Pubitemid 38812631)
42. Gandhi S., Vaarmann A., Yao Z., Duchen M. R., Wood N. W., Abramov A. Y., Dopamine induced neurodegeneration in a PINK1 model of Parkinson's disease. PLoS ONE 2012 7 5 e37564 10.1371/journal.pone.0037564
43. Bozzi Y., Borrelli E., Dopamine in neurotoxicity and neuroprotection: what do D2 receptors have to do with it? Trends in Neurosciences 2006 29 3 167 174 2-s2.0-33644499124 10.1016/j.tins.2006.01.002
44. Bédard C., Wallman M. J., Pourcher E., Gould P. V., Parent A., Parent M., Serotonin and dopamine striatal innervation in Parkinson's disease and Huntington's chorea. Parkinsonism and Related Disorders 2011 17 8 593 598 2-s2.0-79958044957 10.1016/j.parkreldis.2011.05.012
45. Shen L. H., Liao M. H., Tseng Y. C., Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders. Journal of Biomedicine and Biotechnology 2012 2012 14 259349 10.1155/2012/259349
46. Madras B. K., Miller G. M., Fischman A. J., The dopamine transporter and attention-deficit/hyperactivity disorder. Biological Psychiatry 2005 57 11 1397 1409 2-s2.0-20444424891 10.1016/j.biopsych.2004.10.011 (Pubitemid 40798561)
47. Singer H. S., Tourette's syndrome: from behaviour to biology. The Lancet Neurology 2005 4 3 149 159 2-s2.0-13944254442 10.1016/S1474-4422(05)01012-4 (Pubitemid 40269145)
48. O'Neill M. J., Hicks C. A., Ward M. A., Cardwell G. P., Reymann J. M., Allain H., Bentué-Ferrer D., Dopamine D2 receptor agonists protect against ischaemia-induced hippocampal neurodegeneration in global cerebral ischaemia. European Journal of Pharmacology 1998 352 1 37 46 2-s2.0-0031594974 10.1016/S0014-2999(98)00333-1 (Pubitemid 28359405)
49. Bozzi Y., Vallone D., Borrelli E., Neuroprotective role of dopamine against hippocampal cell death. Journal of Neuroscience 2000 20 22 8643 8649 2-s2.0-0034668920
50. Park S. K., Nguyen M. D., Fischer A., Luke M. P., Affar E. B., Dieffenbach P. B., Tseng H. C., Shi Y., Tsai L. H., Par-4 links dopamine signaling and depression. Cell 2005 122 2 275 287 2-s2.0-22744457705 10.1016/j.cell.2005.05.031 (Pubitemid 41032990)
51. Iaccarino C., Samad T. A., Mathis C., Control of lactotrop proliferation by dopamine: essential role of signalling through D2 receptors and ERKs. Proceeding of the National Academy of Sciences USA 2002 99 14530 14535 2-s2.0-0034668920 (Pubitemid 35257705)
52. Webster M. J., Knable M. B., O'Grady J., Orthmann J., Weickert C. S., Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders. Molecular Psychiatry 2002 7 9 985 994 2-s2.0-0036428858 10.1038/sj.mp.4001139 (Pubitemid 35333054)
53. Perlman W. R., Webster M. J., Kleinman J. E., Weickert C. S., Reduced glucocorticoid and estrogen receptor alpha messenger ribonucleic acid levels in the amygdala of patients with major mental illness. Biological Psychiatry 2004 56 11 844 852 2-s2.0-9644302538 10.1016/j.biopsych.2004.09.006 (Pubitemid 39575458)
54. Cotter D., Pariante C. M., Stress and the progression of the developmental hypothesis of schizophrenia. British Journal of Psychiatry 2002 181 363 365 2-s2.0-0036849407 10.1192/bjp.181.5.363 (Pubitemid 35333099)
55. Newcomer J. W., Selke G., Melson A. K., Hershey T., Craft S., Richards K., Alderson A. L., Decreased memory performance in healthy humans induced by stress-level cortisol treatment. Archives of General Psychiatry 1999 56 6 527 533 2-s2.0-0032973470 10.1001/archpsyc.56.6.527 (Pubitemid 29304646)
56. Heffelfinger A. K., Newcomer J. W., Glucocorticoid effects on memory function over the human life span. Development and Psychopathology 2001 13 3 491 513 2-s2.0-0035376202 10.1017/S0954579401003054 (Pubitemid 33406340)
57. Roozendaal B., de Quervain D. J. F., Glucocorticoid therapy and memory function: lessons learned from basic research. Neurology 2005 64 2 184 185 2-s2.0-12544250072
58. Sedvall G., Farde L., Chemical brain anatomy in schizophrenia. The Lancet 1995 346 8977 743 749 2-s2.0-0029119737 10.1016/S0140-6736(95)91508-7
59. Brown P., Understanding the inner voices. New Scientist 1994 143 1933 26 31 2-s2.0-0028010436
60. Hietala J., Syvalahti E., Vuorio K., Rakkolainen V., Bergman J., Haaparanta M., Solin O., Kuoppamaki M., Kirvela O., Ruotsalainen U., Salokangas R. K. R., Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. The Lancet 1995 346 8983 1130 1131 2-s2.0-0028805490
61. Schmauss C., Haroutunian V., Davis K. L., Davidson M., Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 1993 90 19 8942 8946 2-s2.0-0027429027 10.1073/pnas.90.19.8942 (Pubitemid 23306427)
62. Lickey M., Gordon B., Medicine and Mental Illness 1990 New York, NY, USA W. H. Freeman
63. Fahn S., Sulzer D., Neurodegeneration and neuroprotection in Parkinson disease. Neurotherapeutics 2004 1 1 139 154 2-s2.0-3543056130 10.1602/neurorx.1.1.139 (Pubitemid 46589347)
64. Gao H. M., Liu B., Zhang W., Hong J. S., Novel anti-inflammatory therapy for Parkinson's disease. Trends in Pharmacological Sciences 2003 24 8 395 401 2-s2.0-0043162103 10.1016/S0165-6147(03)00176-7 (Pubitemid 36952555)
65. Kurkowska-Jastrzbska I., Litwin T., Joniec I., Ciesielska A., Przybykowski A., Czonkowski A., Czonkowska A., Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease. International Immunopharmacology 2004 4 10-11 1307 1318 2-s2.0-4143096025 10.1016/j.intimp.2004.05.006 (Pubitemid 39094405)
66. Castao A., Herrera A. J., Cano J., Machado A., The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF- α IL-1 β IFN- γ Journal of Neurochemistry 2002 81 1 150 157 2-s2.0-0036077851 10.1046/j.1471-4159.2002.00799.x (Pubitemid 34808862)
67. Kanthasamy A., Jin H., Mehrotra S., Mishra R., Kanthasamy A., Rana A., Novel cell death signaling pathways in neurotoxicity models of dopaminergic degeneration: relevance to oxidative stress and neuroinflammation in Parkinson's disease. NeuroToxicology 2010 31 5 555 561 2-s2.0-77956228435 10.1016/j.neuro.2009.12.003
68. Lange K. W., Robbins T. W., Marsden C. D., James M., Owen A. M., Paul G. M., L-Dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology 1992 107 2-3 394 404 2-s2.0-0026534848
69. Lange K. W., Paul G. M., Naumann M., Gsell W., Dopaminergic effects on cognitive performance in patients with Parkinson's disease. Journal of Neural Transmission, Supplement 1995 46 423 432 2-s2.0-0029414771 (Pubitemid 26043248)
70. Cyr M., Morissette M., Barden N., Beaulieu S., Rochford J., Di Paolo T., Dopaminergic activity in transgenic mice underexpressing glucocorticoid receptors: effect of antidepressants. Neuroscience 2001 102 1 151 158 2-s2.0-0035793021 10.1016/S0306-4522(00)00444-9 (Pubitemid 32171861)
71. Caamao C. A., Morano M. I., Akil H., Corticosteroid receptors: a dynamic interplay between protein folding and homeostatic control. Possible implications in psychiatric disorders. Psychopharmacology Bulletin 2001 35 1 6 23 2-s2.0-0035751311
72. Mizoguchi K., Yuzurihara M., Nagata M., Ishige A., Sasaki H., Tabira T., Dopamine-receptor stimulation in the prefrontal cortex ameliorates stress-induced rotarod impairment. Pharmacology Biochemistry and Behavior 2002 72 3 723 728 2-s2.0-0036011319 10.1016/S0091-3057(02)00747-5 (Pubitemid 34450871)
73. Pariante C. M., Miller A. H., Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biological Psychiatry 2001 49 5 391 404 2-s2.0-0035280252 10.1016/S0006-3223(00)01088-X (Pubitemid 32234301)
74. Fleming S. K., Blasey C., Schatzberg A. F., Neuropsychological correlates of psychotic features in major depressive disorders: a review and meta-analysis. Journal of Psychiatric Research 2004 38 1 27 35 2-s2.0-0348141668 10.1016/S0022-3956(03)00100-6 (Pubitemid 38018987)
75. Lyons D. M., Lopez J. M., Yang C., Schatzberg A. F., Stress-level cortisol treatment impairs inhibitory control of behavior in monkeys. Journal of Neuroscience 2000 20 20 7816 7821 2-s2.0-0034667640
76. Duval F., Mokrani M. C., Crocq M. A., Bailey P. E., Diep T. S., Correa H., Macher J. P., Dopaminergic function and the cortisol response to dexamethasone in psychotic depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2000 24 2 207 225 2-s2.0-0034144591 10.1016/S0278-5846(99) 00098-6 (Pubitemid 30159530)
77. de Quervain D. J. F., Roozendaal B., McGaugh J. L., Stress and glucocorticoids impair retrieval of long-term spatial memory. Nature 1998 394 6695 787 790 2-s2.0-0032552049 10.1038/29542 (Pubitemid 28391643)
78. Calabrese J. R., Markovitz P. J., Treatment of depression: new pharmacologic approaches. Primary Care 1991 18 2 421 433 2-s2.0-0026328321
79. van der Lely A. J., Foeken K., van der Mast R. C., Lamberts S. W. J., Rapid reversal of acute psychosis in the Cushing syndrome with the cortisol-receptor antagonist mifepristone (RU 486). Annals of Internal Medicine 1991 114 2 143 144 2-s2.0-0026019646
80. Sartor O., Cutler G. B. Jr., Mifepristone: treatment of Cushing's syndrome. Clinical Obstetrics and Gynecology 1996 39 2 506 510 2-s2.0-0029946097 10.1097/00003081-199606000-00024 (Pubitemid 26143728)
81. Belanoff J. K., Rothschild A. J., Cassidy F., DeBattista C., Baulieu E. E., Schold C., Schatzberg A. F., An open label trial of C-1073 (mifepristone) for psychotic major depression. Biological Psychiatry 2002 52 5 386 392 2-s2.0-0036752158 10.1016/S0006-3223(02)01432-4 (Pubitemid 35266729)
82. Chu J. W., Matthias D. F., Belanoff J., Schatzberg A., Hoffman A. R., Feldman D., Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). Journal of Clinical Endocrinology and Metabolism 2001 86 8 3568 3573 2-s2.0-0034880195 10.1210/jc.86.8.3568 (Pubitemid 32755945)
83. Basta-Kaim A., Budziszewska B., Jaworska-Feil L., Tetich M., Kubera M., Lekiewicz M., Laso W., Mood stabilizers inhibit glucocorticoid receptor function in LMCAT cells. European Journal of Pharmacology 2004 495 2-3 103 110 2-s2.0-3042831746 10.1016/j.ejphar.2004.05.034 (Pubitemid 38891866)
84. Wei Q., Lu X. Y., Liu L., Schafer G., Shieh K. R., Burke S., Robinson T. E., Watson S. J., Seasholtz A. F., Akil H., Glucocorticoid receptor overexpression in forebrain: a mouse model of increased emotional lability. Proceedings of the National Academy of Sciences of the United States of America 2004 101 32 11851 11856 2-s2.0-4143091546 10.1073/pnas.0402208101 (Pubitemid 39095383)
85. Piazza P. V., Le Moal M., The role of stress in drug self-administration. Trends in Pharmacological Sciences 1998 19 2 67 74 2-s2.0-0031906165 10.1016/S0165-6147(97)01115-2 (Pubitemid 28137716)
86. Piazza P. V., Barrot M., Rougé-Pont F., Marinelli M., Maccari S., Abrous D. N., Simon H., Le Moal M., Suppression of glucocorticoid secretion and antipsychotic drugs have similar effects on the mesolimbic dopaminergic transmission. Proceedings of the National Academy of Sciences of the United States of America 1996 93 26 15445 15450 2-s2.0-0030479073 10.1073/pnas.93.26. 15445 (Pubitemid 27009619)
87. Piazza P. V., Deroche-Gamonent V., Rouge-Pont F., Le Moal M., Vertical shifts in self-administration dose-response functions predict a drug-vulnerable phenotype predisposed to addiction. Journal of Neuroscience 2000 20 11 4226 4232 2-s2.0-0034212706 (Pubitemid 30365693)
88. Marinelli M., Aouizerate B., Barrot M., Le Moal M., Piazza P. V., Dopamine-dependent responses to morphine depend on glucocorticoid receptors. Proceedings of the National Academy of Sciences of the United States of America 1998 95 13 7742 7747 2-s2.0-0032560530 10.1073/pnas.95.13.7742 (Pubitemid 28293324)
89. Deroche-Gamonet V., Sillaber I., Aouizerate B., Izawa R., Jaber M., Ghozland S., Kellendonk C., Le Moal M., Spanagel R., Schütz G., Tronche F., Piazza P. V., The glucocorticoid receptor as a potential target to reduce cocaine abuse. Journal of Neuroscience 2003 23 11 4785 4790 2-s2.0-0038456111 (Pubitemid 36706207)
90. Pacak K., Tjurmina O., Palkovits M., Goldstein D. S., Koch C. A., Hoff T., Chrousos G. P., Chronic hypercortisolemia inhibits dopamine synthesis and turnover in the nucleus accumbens: an in vivo microdialysis study. Neuroendocrinology 2002 76 3 148 157 2-s2.0-0036976830 10.1159/000064522 (Pubitemid 36152979)
91. de Jong I. E. M., de Kloet E. R., Glucocorticoids and vulnerability to psychostimulant drugs: toward substrate and mechanism. Annals of the New York Academy of Sciences 2004 1018 192 198 2-s2.0-3242712114 10.1196/annals.1296.022 (Pubitemid 38951406)
92. Taché Y., Yang H., Miampamba M., Martinez V., Yuan P. Q., Role of brainstem TRH/TRH-R1 receptors in the vagal gastric cholinergic response to various stimuli including sham-feeding. Autonomic Neuroscience: Basic and Clinical 2006 125 1-2 42 52 2-s2.0-33646479466 10.1016/j.autneu.2006.01.014
93. Ericsson P., Håkanson R., Rehfeld J. F., Norlén P., Gastrin release: antrum microdialysis reveals a complex neural control. Regulatory Peptides 2010 161 13 22 32 2-s2.0-77950340320 10.1016/j.regpep.2010.01.004
94. Glavin G. B., Activity of selective dopamine DA1 and DA2 agonists and antagonists on experimental gastric lesions and gastric acid secretion. Journal of Pharmacology and Experimental Therapeutics 1989 251 2 726 730 2-s2.0-0024307198 (Pubitemid 20005622)
95. Chandranath S. I., Bastaki S. M. A., D'Souza A., Adem A., Singh J., Attenuation of stress-induced gastric lesions by lansoprazole, PD-136450 and ranitidine in rats. Molecular and Cellular Biochemistry 2011 349 1-2 205 212 2-s2.0-79952282057 10.1007/s11010-010-0675-3
96. Brzozowski T., Konturek P. C., Chlopicki S., Sliwowski Z., Pawlik M., Ptak-Belowska A., Kwiecie S., Drozdowicz D., Pajdo R., Slonimska E., Konturek S. J., Pawlik W. W., Therapeutic potential of 1-methylnicotinamide against acute gastric lesions induced by stress: role of endogenous prostacyclin and sensory nerves. Journal of Pharmacology and Experimental Therapeutics 2008 326 1 105 116 2-s2.0-45749132575 10.1124/jpet.108.136457 (Pubitemid 351872128)
97. Yigiter M., Albayrak Y., Polat B., Suleyman B., Salman A. B., Suleyman H., Influence of adrenal hormones in the occurrence and prevention of stress ulcers. Journal of Pediatric Surgery 2010 45 11 2154 2159 2-s2.0-78049481430 10.1016/j.jpedsurg.2010.07.027
98. Choung R. S., Talley N. J., Epidemiology and clinical presentation of stress-related peptic damage and chronic peptic ulcer. Current Molecular Medicine 2008 8 4 253 257 2-s2.0-47249151034 10.2174/156652408784533823 (Pubitemid 351982529)
99. Fink G., Stress controversies: post-traumatic stress disorder, hippocampal volume, gastroduodenal ulceration. Journal of Neuroendocrinology 2011 23 2 107 117 2-s2.0-78651087124 10.1111/j.1365-2826.2010.02089.x
100. Schubert M. L., Gastric exocrine and endocrine secretion. Current Opinion in Gastroenterology 2009 25 6 529 536 2-s2.0-74549210726 10.1097/MOG. 0b013e328331b62a
101. Strang R. R., The association of gastro-duodenal ulceration and Parkinson's disease. The Medical Journal of Australia 1965 310 842 843 2-s2.0-76549205291
102. Szabo S., Dopamine disorder in duodenal ulceration. The Lancet 1979 2 8148 880 882 2-s2.0-0018597201 (Pubitemid 10157839)
103. Chung E. S., Chung Y. C., Bok E., Baik H. H., Park E. S., Park J. Y., Yoon S. H., Jin B. K., Fluoxetine prevents LPS-induced degeneration of nigral dopaminergic neurons by inhibiting microglia-mediated oxidative stress. Brain Research 2010 1363 143 150 2-s2.0-78149470860 10.1016/j.brainres.2010.09.049
104. Kumar A., Prakash A., Pahwa D., Galantamine potentiates the protective effect of rofecoxib and caffeic acid against intrahippocampal Kainic acid-induced cognitive dysfunction in rat. Brain Research Bulletin 2011 85 3-4 158 168 2-s2.0-79957864085 10.1016/j.brainresbull.2011.03.010
105. Roghani M., Niknam A., Jalali-Nadoushan M. R., Kiasalari Z., Khalili M., Baluchnejadmojarad T., Oral pelargonidin exerts dose-dependent neuroprotection in 6-hydroxydopamine rat model of hemi-parkinsonism. Brain Research Bulletin 2010 82 5-6 279 283 2-s2.0-77955091096 10.1016/j.brainresbull.2010.06.004
106. Glavin G. B., Dopamine and gastroprotection. The brain-gut axis. Digestive Diseases and Sciences 1991 36 12 1670 1672 2-s2.0-0025788277
107. Mayer E. A., The neurobiology of stress and gastrointestinal disease. Gut 2000 47 6 861 869 2-s2.0-0033676266 10.1136/gut.47.6.861
108. Gray S. J., Benson J. A., Reifenstein R. W., Chronic stress and peptic ulcer. I. Effect of corticotropin (ACTH) and cortisone on gastric secretion. The Journal of the American Medical Association 1951 147 16 1529 1537 10.1001/jama.1951.03670330021007
109. Willems J. L., Buylaert W. A., Lefebvre R. A., Bogaert M. G., Neuronal dopamine receptors on autonomic ganglia and sympathetic nerves and dopamine receptors in the gastrointestinal system. Pharmacological Reviews 1985 37 2 165 216 2-s2.0-0022245501 (Pubitemid 16256772)
110. Glavin G. B., Dopamine: a stress modulator in the brain and gut. General Pharmacology 1992 23 6 1023 1026 2-s2.0-0026497762 10.1016/0306-3623(92)90281-N
111. Xing L. P., Balaban C., Seaton J., Washington J., Kauffman G., Mesolimbic dopamine mediates gastric mucosal protection by central neurotensin. American Journal of Physiology 1991 260 1 G34 G38 2-s2.0-0025965091
112. Henke P. G., Limbic lesions and the energizing, aversive, and inhibitory effects of non-reward in rats. Canadian Journal of Psychology 1979 33 3 133 140 2-s2.0-0018510866
113. Hoogerwerf W., Pasricha P. J., Brunton L. L., Lazo J. S., Parker K. L., Pharmacotherapy of gastric acidity, peptic ulcers, and gastroesophageal reflux disease. The Pharmacological Basis of Therapeutics 2006 New York, NY, USA Mc Graw Hill 967 981
114. Valle J. D., Fauci A. S., Braunwald E., Kasper D. L., Hauser S. L., Longo D. L., Jameson J. L., Loscalzo J., Peptic ulcer disease and related disorders. Harrison's Principles of Internal Medicine 2008 New York, NY, USA Mc Graw Hill 1855 1871